Alvina D. Chu

5.2k total citations · 4 hit papers
34 papers, 2.2k citations indexed

About

Alvina D. Chu is a scholar working on Genetics, Dermatology and Immunology and Allergy. According to data from OpenAlex, Alvina D. Chu has authored 34 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 13 papers in Dermatology and 12 papers in Immunology and Allergy. Recurrent topics in Alvina D. Chu's work include Chronic Lymphocytic Leukemia Research (13 papers), Dermatology and Skin Diseases (13 papers) and Lymphoma Diagnosis and Treatment (10 papers). Alvina D. Chu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Dermatology and Skin Diseases (13 papers) and Lymphoma Diagnosis and Treatment (10 papers). Alvina D. Chu collaborates with scholars based in United States, Germany and Canada. Alvina D. Chu's co-authors include Henrique D. Teixeira, John Liu, Barry Ladizinski, Eric L. Simpson, Andrew Blauvelt, Marjolein de Bruin‐Weller, Xiaofei Hu, Aileen L. Pangan, Norito Katoh and Antonio Costanzo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Alvina D. Chu

33 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. The Lancet profile →
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

2021 305 citations Andrew Blauvelt, Henrique D. Teixeira et al. profile →
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

2021 250 citations Kristian Reich, Henrique D. Teixeira et al. The Lancet profile →
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

2022 122 citations Eric L. Simpson, Kim Papp et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alvina D. Chu United States	18	1.1k	842	729	728	437	34	2.2k
Fabio P. Nunes United States	21	876 0.8×	363 0.4×	557 0.8×	175 0.2×	136 0.3×	43	1.7k
Romeo Maciuca United States	13	59 0.1×	1.6k 1.9×	197 0.3×	1.3k 1.8×	204 0.5×	29	2.5k
Valérie Devauchelle France	26	54 0.1×	874 1.0×	44 0.1×	876 1.2×	165 0.4×	57	2.2k
Fabien B. Vincent Australia	19	51 0.0×	788 0.9×	40 0.1×	1.2k 1.6×	178 0.4×	34	1.8k
Lucio Manenti Italy	18	131 0.1×	463 0.5×	55 0.1×	231 0.3×	50 0.1×	44	1.1k
Yacine Salhi United States	15	181 0.2×	79 0.1×	168 0.2×	95 0.1×	86 0.2×	32	1.7k
Masashi Akizuki Japan	19	85 0.1×	568 0.7×	29 0.0×	302 0.4×	241 0.6×	42	1.2k
Friedrich Wimazal Austria	24	18 0.0×	351 0.4×	333 0.5×	722 1.0×	152 0.3×	52	2.0k
Apostolos Kontzias United States	15	76 0.1×	308 0.4×	27 0.0×	409 0.6×	117 0.3×	31	1.3k
Elvira Favoino Italy	19	70 0.1×	164 0.2×	47 0.1×	436 0.6×	248 0.6×	51	1.2k

Countries citing papers authored by Alvina D. Chu

Since Specialization

Citations

This map shows the geographic impact of Alvina D. Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alvina D. Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alvina D. Chu more than expected).

Fields of papers citing papers by Alvina D. Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alvina D. Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alvina D. Chu. The network helps show where Alvina D. Chu may publish in the future.

Co-authorship network of co-authors of Alvina D. Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Alvina D. Chu. A scholar is included among the top collaborators of Alvina D. Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alvina D. Chu. Alvina D. Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qian, Yuli, Eliza M. Raymundo, Kristina Unnebrink, et al.. (2024). Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis. Clinical Therapeutics. 46(10). 733–741. 3 indexed citations

Simpson, Eric L., Xiaofei Hu, Alvina D. Chu, et al.. (2023). Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials. Journal of the European Academy of Dermatology and Venereology. 37(9). 1863–1870. 17 indexed citations

Ismail, Mohamed A., et al.. (2023). Population pharmacokinetic and exposure‐response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis. British Journal of Clinical Pharmacology. 89(10). 3139–3151. 10 indexed citations

Guttman‐Yassky, Emma, Jacob P. Thyssen, Jonathan I. Silverberg, et al.. (2022). Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. Journal of Allergy and Clinical Immunology. 151(1). 172–181. 43 indexed citations

Silverberg, Jonathan I., Marjolein de Bruin‐Weller, Thomas Bieber, et al.. (2021). Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. Journal of Allergy and Clinical Immunology. 149(3). 977–987.e14. 76 indexed citations

Reich, Kristian, Henrique D. Teixeira, Marjolein de Bruin‐Weller, et al.. (2021). Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 397(10290). 2169–2181. 250 indexed citations breakdown →

Guttman‐Yassky, Emma, Henrique D. Teixeira, Eric L. Simpson, et al.. (2021). Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. The Lancet. 397(10290). 2151–2168. 350 indexed citations breakdown →

Heijde, Désirée van der, Aileen L. Pangan, Atul Deodhar, et al.. (2019). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. The Lancet. 394(10214). 2108–2117. 242 indexed citations

Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512. 32 indexed citations

10.

O’Brien, Susan, Samantha Jaglowski, John C. Byrd, et al.. (2018). Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia. JAMA Oncology. 4(5). 712–712. 16 indexed citations

11.

Fowler, Nathan, Ian W. Flinn, Simon Rule, et al.. (2017). A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE).. Journal of Clinical Oncology. 35(15_suppl). TPS7576–TPS7576. 1 indexed citations

12.

O’Brien, Susan, Richard R. Furman, Steven Coutré, et al.. (2016). Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood. 128(22). 233–233. 65 indexed citations

13.

Yiu, Gloria, Tue Kruse Rasmussen, Bahareh Ajami, et al.. (2015). Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1. Arthritis & Rheumatology. 68(5). 1233–1244. 8 indexed citations

14.

Newell, Evan W., Justin A. Jarrell, Alvina D. Chu, et al.. (2015). Tetramers reveal IL-17–secreting CD4⁺T cells that are specific for U1-70 in lupus and mixed connective tissue disease. Proceedings of the National Academy of Sciences. 112(10). 3044–3049. 23 indexed citations

15.

Richard, Florence, Morton Scheinberg, Alvina D. Chu, et al.. (2014). FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies. Annals of the Rheumatic Diseases. 73. 527–528. 1 indexed citations

16.

Furie, Richard, G. Léon, Michelle Petri, et al.. (2014). A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Annals of the Rheumatic Diseases. 74(9). 1667–1675. 127 indexed citations

17.

Furie, R., Morton Scheinberg, G. Léon, et al.. (2013). OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE. Annals of the Rheumatic Diseases. 72. A90–A91. 4 indexed citations

18.

Qin, Huilian, I‐Fang Lee, Constadina Panagiotopoulos, et al.. (2011). Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling. Diabetes. 60(3). 857–866. 50 indexed citations

19.

Strand, Vibeke & Alvina D. Chu. (2011). Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Review of Pharmacoeconomics & Outcomes Research. 11(4). 455–468. 33 indexed citations

20.

Chu, Alvina D., Kareem L. Graham, Imelda Balboni, et al.. (2008). IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. Journal of Clinical Investigation. 118(4). 1417–1426. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact